Tornado Global Hydrovacs Stock (OTC: TGHLF)

Latest news for Tornado Global Hydrovacs (OTC:TGHLF) Stock

Tornado Global Hydrovacs Ltd is a truck manufacturer. The company, through its subsidiaries, designs, fabricates, manufactures, and sells hydro vac trucks to excavation service providers in the municipal and oil and gas markets in North America and has expanded into China. It has two geographic operating segments, North American manufacturing and sales operations, and its China operation. The majority of its revenue is derived from the North American manufacturing segment.

TORNADO GLOBAL HYDROVACS by Tornado Global Hydrovacs Ltd.

Tornado Global Hydrovacs Ltd

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $68 price target.

News

Price Target

Reiteration

Analyst Ratings

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $68 Price Target

Wells Fargo analyst Stephen Baxter downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Overweight to Equal-Weight and lowers the price target from $205 to $150.

Downgrades

Wells Fargo Downgrades Tenet Healthcare to Equal-Weight, Lowers Price Target to $150

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and maintains $41 price target.

RNAC

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target

Catalyst Bancorp, Inc. (Nasdaq: "CLST") (the "Company"), the parent company for Catalyst Bank (the "Bank") (<a href="http://www.catalystbank.com/">www.catalystbank.com</a>), announced today that the Board of Directors approved the Company's fifth share repurchase plan.&nbsp;
"It has been over three years since we embarked on our public company journey. We've set ambitious goals to transform ourselves into a consistently strong performing community bank. High among those goals is focusing our mission on serving as catalysts to help local businesses grow – because when they do, they create jobs in our communities. We rebranded as Catalyst Bank to reinforce our commitment," said Joe Zanco, President and Chief Executive Officer of the Company and Bank.
"We have expanded our branch network into the business center of our region, adding locations in Carencro and Lafayette, Louisiana. Although we increased our branch count by two, or 50%, we have held our employee count steady by focusing on enhancing efficiency throughout the Company.&nbsp;
"We have upgraded our systems and now offer some of the very best in banking technology. The systems upgrade reduces non-interest expense over $200,000 annually and also facilitates additional efficiency gains.&nbsp;
"Our collective efforts have resulted in meaningful customer growth, especially in 2024.&nbsp; In fact, loan growth through the third quarter was a record $21 million.&nbsp; As a result of organic customer growth and greater efficiency, our core profitability continues to improve.&nbsp;
"Not everything has gone according to plan since our IPO. At the outset of our journey, we believed there might be opportunities to acquire one or more banks during the first three years following our IPO, which would have allowed us to expand our footprint and enhance profitability more rapidly. Unfortunately, the right opportunities have not presented themselves to date.&nbsp; However, we still have the capital and management depth and expertise to take advantage of desirable opportunities should they present themselves in the near future.&nbsp;
"Today, we announced our fifth share repurchase plan (the "November 2024 Repurchase Plan").&nbsp; Under the November 2024 Repurchase Plan, the Company may purchase up to 215,000 shares, or approximately 5%, of the Company's outstanding common stock. Since the announcement of our first share repurchase plan in January 2023 and through November 22, 2024, the Company has repurchased a total of 972,916 shares of its common stock, or approximately 18% of the common shares originally issued, at an average cost per share of $11.93.
"As we enter the new year, know that we are focused on serving our customers tremendously well, deepening the skills of our employees and enhancing our profitability and shareholder value.&nbsp; What we've achieved since our IPO is the result of the efforts of our dynamic team.&nbsp; Our commitment to growing and further improving our company is stronger than ever."

Buybacks

CLST

Catalyst Bancorp Announces Fifth Stock Buyback Plan, Targeting 215,000 Shares

Wells Fargo analyst Stephen Baxter downgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Equal-Weight to Underweight and lowers the price target from $400 to $320.

Wells Fargo Downgrades HCA Healthcare to Underweight, Lowers Price Target to $320

Biotech

Health Care

Financing

Offerings

General

REPL

Replimune Has Proposed Public Offering Of $125M Of Its Common Stock And Pre-funded Warrants To Purchase Shares, The Underwriter Has A 30-day Option To Purchase Up To An Additional $18.75 Million Of Securities

Smartkem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>), positioned to power the next generation of displays using its disruptive organic thin-film transistors (OTFTs), has partnered with AUO, the largest display manufacturer in Taiwan, to jointly develop the world's first advanced rollable, transparent microLED display using Smartkem's technology.
"We believe that collaborating with global display industry leader AUO to develop a novel microLED display puts Smartkem's technology on the frontier of microLED display commercialization. Our unique transistor technology is expected to enable display manufacturers to efficiently produce microLED displays, making mass production commercially viable. Smartkem's technology has the potential to take today's microLED TVs from high end market prices of $100,000 down to mass market prices," stated Ian Jenks, Smartkem Chairman and CEO.
"Because our transistors are processed at such a low temperature compared to other technologies, we are able to pour them directly on top of the microLEDs, completely eliminating the problematic mass transfer and laser welding processes required with other technologies. The key feature that enables the development of this microLED display is our unique low temperature process that allows the use of low-cost, flexible plastic rather than glass. We believe that, if successful, this collaboration will be a significant milestone for Smartkem in its road to commercialization, and for microLED display product development using our technology."
Dr. Wei-Lung Liau, Chief Technology Officer of AUO, commented, "AUO has dedicated years to developing the ultimate MicroLED display technology, forging alliances with ecosystem partners to enable mass production. In this collaboration, AUO has developed groundbreaking technologies that boost the high transparency and free-form in applications of MicroLED. With proprietary materials from Smartkem and the OTFT production process from ITRI, we are collaboratively developing the world's first rollable MicroLED display for potential commercialization with cost advantage. We believe this will create new opportunities for the display industry and continue to expand value chain partner cooperation and influence."
Leading display analyst and DSCC (Display Supply Chain Consultants) CEO, Ross Young, commented, "This is an exciting project that, if successful, will demonstrate the cost effectiveness of Smartkem's technology in the most demanding of MicroLED applications, and could generate substantial market interest."
Smartkem's Disruption to the MicroLED Display Market Smartkem believes it is poised to transform the display industry with a new class of microLED displays that are low-cost, thin, transparent, flexible and lightweight. This is made possible by Smartkem's OTFTs that are processed at an industry comparatively low temperature, enabling them to be processed directly on top of microLEDs in the manufacturing of microLED displays, eliminating the need for mass transfer and laser welding processes required by existing technology. This introduces an entirely new "Chip-First" display architecture to the display market that is not currently possible using other transistor technologies. Additionally, Smartkem's low temperature feature enables processing of Smartkem's OTFTs on a plastic substrate, rather than glass, that is low-cost, thin, transparent, flexible and lightweight.
The project between Smartkem and AUO will commence on January 1, 2025. The collaboration has been awarded a grant from the 2024 Taiwan-UK Research &amp; Development Collaboration, supported by The Taiwanese Ministry of Economic Affairs and Innovate UK, part of UK Research and Innovation (UKRI).
About the 2024 UK-Taiwan Collaborative R&amp;D Initiative The 2024 UK-Taiwan Collaborative R&amp;D Initiative has invested more than £10 million this year to promote bilateral industrial technology research and development cooperation. The nine award-winning projects will promote the joint development of advanced technologies in fields such as electrical information communication, biomedicine, and electromechanical by Taiwan-UK enterprises.

SMTK

Smartkem Partners With AUO To Develop Rollable, Transparent MicroLED Displays

Wells Fargo analyst Stephen Baxter downgrades Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) from Equal-Weight to Underweight and lowers the price target from $5 to $2.5.

Wells Fargo Downgrades Community Health Sys to Underweight, Lowers Price Target to $2.5

The effective date of the reverse stock split has not yet been determined and will be announced by the Company at least two business days prior to its implementation.

Stock Split

RNAZ

TransCode Therapeutics Has Approved A 1-for-33 Reverse Stock Split

Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin (BTC) activity and holdings, capital markets activity, and BTC yield, a key performance indicator.
&nbsp;
BTC Update
Between November 18, 2024 and November 22, 2024, Semler Scientific acquired 297 bitcoins for $29.1 million in cash, at an average price of $97,995 per bitcoin, inclusive of fees and expenses. As of November 22, 2024, Semler Scientific held 1,570 bitcoins, which were acquired for an aggregate $117.8 million at an average purchase price of $75,039 per bitcoin, inclusive of fees and expenses.
ATM Update
As previously disclosed in Semler Scientific's registration statement on Form S-3 that became effective on August 13, 2024 (the S-3 Shelf), Semler Scientific entered into a Controlled Equity OfferingSM&nbsp;Sales Agreement with Cantor Fitzgerald &amp; Co. (Cantor), pursuant to which Semler Scientific may offer and sell from time to time its common stock in an at-the-market (ATM) offering.
Today, Semler Scientific filed a prospectus supplement to its S-3 Shelf to offer an additional $50.0 million of shares under its existing ATM offering with Cantor, increasing the total amount offered under the ATM to $100.0 million.&nbsp; As of November 22, 2024, Semler Scientific has generated approximately $50.0 million of gross proceeds under the ATM offering.
BTC Yield as a Key Performance Indicator (KPI)
From October 1, 2024 to November 22, 2024, Semler Scientific's BTC Yield was 37.1%. From July 1, 2024 (the quarter after Semler Scientific adopted its bitcoin treasury strategy) to November 22, 2024, Semler Scientific's BTC Yield was 58.4%.
"We are thrilled to report a 58.4% BTC Yield and the outstanding progress we are making to accumulate bitcoin on our balance sheet in a highly accretive way for our stakeholders," said Eric Semler, chairman of Semler Scientific.
Semler Scientific uses BTC Yield as a KPI to help assess the performance of its strategy of acquiring bitcoin in a manner Semler Scientific believes is accretive to stockholders. Semler Scientific believes this KPI can be used to supplement an investor's understanding of Semler Scientific's decision to fund the purchase of bitcoin by issuing additional shares of its common stock.
BTC Yield and Basic and Assumed Diluted Shares Outstanding
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6/30/2024&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">9/30/2024&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">11/22/2024&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total&nbsp;Bitcoin&nbsp;Holdings</td>
<td colspan="1" rowspan="1">877</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,018</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,570</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Basic&nbsp;Shares Outstanding&nbsp;('000)</td>
<td colspan="1" rowspan="1">6,987</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7,120</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">8,289</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Options&nbsp;Outstanding</td>
<td colspan="1" rowspan="1">1,098</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,013</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">855</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Assumed&nbsp;Diluted&nbsp;Shares&nbsp;Outstanding&nbsp;(1)</td>
<td colspan="1" rowspan="1">8,086</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">8,133</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">9,143</td>
</tr>
<tr>
<td colspan="1" rowspan="1">BTC&nbsp;Yield&nbsp;%&nbsp;(10/1/24 to 11/22/24)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">37.1&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">BTC&nbsp;Yield&nbsp;%&nbsp;(7/1/2024 to 11/22/2024)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">58.4&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>

SMLR

Semler Scientific Increases Bitcoin Holdings to 1,570 BTC With 58.4% Yield, Announces $50M ATM Launch, Adds 297 BTC to Portfolio

Guidance

CRGO

Freightos Expects Q4 Revenue Of $6.4M - $6.5M (Est $6.587M)

<ul>
<li>50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome.</li>
<li>Biopsy results confirmed the presence and persistence of gamma-delta T cells along with CD3+ and CD8+ T cells within the brain tumor microenvironment in two patients following treatment with INB-200.</li>
<li>Patients in the multi-dose cohorts demonstrated a trend toward improved peripheral T cell recovery, suggesting potential immune system benefits.</li>
<li>The majority of patients exceeded their expected progression free survival (PFS) based on age and tumor status; five patients remain alive and three patients have returned to their occupations, with one patient remaining progression free at 40.5 months post treatment.</li>
</ul>

INAB

IN8Bio Presented Results From The Fully Enrolled Phase 1 Trial Of INB-200 At The Annual Meeting Society For Neuro-oncology

2024 Guidance
The company expects the 13-week fourth quarter 2024 net sales to range between a decline of 6.5% to a decline of 4.5%, compared to $2,912 million for the 14-week fourth quarter 2023. We expect fourth quarter net sales will incur a headwind of approximately 500 basis points due to the shifted fiscal calendar, resulting from and including the extra week in 2023. Fourth quarter earnings per diluted share is expected to be between $1.94 and $2.07, compared to $2.55 in the fourth quarter 2023, and adjusted earnings per diluted share of $2.06 in the fourth quarter 2023.

Earnings

BBWI

Bath & Body Works Expects Q4 Net Sales To Decline Of 6.5% To Decline Of 4.5%; Sees EPS Of $1.94-$2.07 Vs. $1.97 Est.

Freightos Says Full-year Revenue Guidance Now At Higher End Of Previous Range; Revises Forecast From $23.4M - $23.7M To $23.6M - $ 23.7M (Est $23.549M)

Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating&nbsp;symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system&nbsp;and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's&nbsp;needs along with the company's Navitor&#x2122; TAVI system, which is already commercially available.
The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening. Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1
The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.

Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang emphasized the company&#8217;s quarter-century presence in China&#8217;s technology ecosystem during a speech at the Hong Kong University of Science and Technology, highlighting how the region helped shape the now-dominant artificial intelligence chip giant.
What Happened: Speaking at HKUST&#8217;s 2024 Congregation, Huang <a href="https://www.youtube.com/watch?v=_gYHTjbguM8">revealed</a> that Nvidia&#8217;s design centers in Hong Kong, Beijing, and Shenzhen have been instrumental in building both the company and China&#8217;s broader technology landscape. 
&#8220;We&#8217;ve had the benefit, the great joy, and the privilege of watching the amazing technology industry form in China,&#8221; Huang said.
The comments come as Nvidia rides unprecedented demand for its AI chips, with recent third-quarter revenue reaching $35.1 billion, up 94% year-over-year. The company&#8217;s data center segment alone generated $30.8 billion, underlining its <a href="https://www.benzinga.com/24/11/42102796/nvidia-projects-gross-margin-recovery-as-blackwell-systems-drive-unprecedented-ai-demand">dominance in AI computing infrastructure</a>.
See Also: <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A &#8216;Primetime&#8217; Year For AI</a>
Why It Matters: Previously, Huang disclosed a significant missed opportunity during an AI summit in Tokyo. He expressed regret at declining SoftBank Group CEO Masayoshi Son&#8216;s offer years ago to finance a complete buyout of Nvidia, <a href="https://www.benzinga.com/markets/equities/24/11/41962451/nvidias-ceo-reveals-the-massive-deal-he-missed-and-why-it-is-today-a-3-6-trillion-regret">now valued at $3.6 trillion</a>.
The CEO&#8217;s remarks at HKUST highlighted AI&#8217;s transformative impact across industries, citing recent Nobel Prize victories in physics and chemistry related to neural networks and protein prediction. &#8220;AI is certainly the most important technology of our time and potentially of all time,&#8221; Huang stated.
Wall Street remains bullish on Nvidia&#8217;s trajectory, with Wedbush analyst Dan Ives describing recent results as a &#8220;jaw-dropper.&#8221; The company projects <a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips">fourth-quarter revenue</a> of $37.5 billion, supported by major deployments like Oracle Corp.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) planned AI computing clusters using over 131,000 Blackwell GPUs.
Price Action: Nvidia&#8217;s stock has surged more than 194.69% year-to-date, outperforming other major tech companies including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42156013/bluesky-adds-millions-of-users-as-elon-musks-social-media-platform-faces-exodus-post-trump-win-here-are-a-few-starter-packs-to-help-you-get-going-on-latest-x-rival">Bluesky Adds Millions Of Users As Elon Musk&#8217;s X Faces Exodus Post Trump Victory: Here Are A Few Starter Packs To Help You Level Up On The Platform</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Nvidia Corp on Flickr<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Entrepreneurship

Global

Markets

Tech

AAPL

MSFT

NVDA

ORCL

Jensen Huang Credits China's 'Amazing' Tech Ecosystem For Helping Shape AI Giant Nvidia

ALNY

The FDA Has Alnylam Pharmaceuticals' Supplemental Marketing Application For Vutrisiran For ATTR Amyloidosis With Cardiomyopathy, Based On The Company's Use Of A Priority Review Voucher, FDA Has Set An Action Date Goal Of March 23, 2025

Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>), a global innovator in advanced connectivity solutions, today announced it has agreed to acquire Spacecraft Components Corp., a Nevada-based leader in high-precision, mission-critical components for aerospace, defense, and commercial applications. The acquisition, which is expected to close in the first quarter of 2025, represents a significant strategic milestone for Mobix Labs as it expands its presence into new markets and strengthens its leadership in key industries.
Spacecraft Components is recognized for its cutting-edge engineering and manufacturing capabilities. Spacecraft delivers electrical connector components and accessories that are vital to mission critical missile technology, submarines, naval ships, oil rigs, railcars, military and commercial jet aircraft, and many other applications. Notably, its components are utilized in the Patriot Missile—the U.S. Army's primary missile defense system—and tactical manned and autonomous vehicles. Additionally, Spacecraft supplies key components for railcar systems in major metropolitan areas such as Chicago and New York.
Strategic Fit and Market Expansion
As a long-standing supplier to Mobix Labs, Spacecraft Components Corp. has provided high-quality components for Mobix Labs' products. This acquisition is a natural fit, allowing Mobix Labs to integrate Spacecraft's expertise and expand into the aerospace, military, and defense sectors; while also entering the transportation market as a new revenue stream.
"This acquisition is transformative for Mobix Labs, aligning with our strategy to diversify our markets and strengthen our position in mission-critical industries," said Fabian Battaglia, CEO of Mobix Labs. "Spacecraft's exceptional reputation and product offerings, combined with Mobix Labs' innovation and expertise, will drive significant growth opportunities for both companies. We are thrilled to welcome their talented team to Mobix Labs as we shape a stronger future together."
Operational and Financial Impact
The acquisition is expected to increase Mobix Labs' workforce by approximately 150 employees, primarily based in Nevada. Spacecraft Components reported unaudited revenues of $18.1 million in 2023, with forecasted growth for the next two years. Spacecraft's compiled unaudited non-GAAP financials represent it has positive earnings and cash flow. The acquisition is expected to be accretive to Mobix Labs' earnings. If the transaction closes as anticipated, it will materially increase Mobix Labs' revenue in fiscal year 2025.
"This partnership provides an exciting opportunity for Spacecraft to grow alongside Mobix Labs," said Craig Wiseman, President of Spacecraft Components. Wiseman also stated that "by combining our manufacturing expertise with Mobix Labs' advanced technologies, we are poised to deliver even greater value to our customers across the aerospace, defense, and transportation sectors."
Transaction Details and Closing Conditions
The terms of the transaction include a purchase price ranging from $18 million to $24 million, with consideration to be paid in a combination of cash and equity, subject to earnout provisions, all of which will be finalized subject to completion of due diligence. The deal remains subject to final due diligence and the approval of the boards of directors of both companies.

MOBX

Mobix Labs Acquires Spacecraft Components in $18M-$24M Deal

For fiscal 2024, the company has raised its full-year net sales and earnings guidance from the guidance provided in August. We now expect net sales to range between a decline of 2.5% to a decline of 1.7%, relative to $7,429 million in fiscal 2023. The 53rd week in fiscal 2023 represents a headwind of approximately 100 basis points to net sales change in fiscal 2024. Full-year 2024 earnings per diluted share is now expected to be between $3.46 and $3.59, compared to earnings per diluted share of $3.84 in 2023. Full-year 2024 adjusted earnings per diluted share is now expected to be between $3.15 and $3.28, compared to adjusted earnings per diluted share of $3.27 in fiscal 2023. The company's full-year guidance includes the anticipated impact of $400 million of cash deployed towards share repurchases.

Bath & Body Works Raises 2024 Guidance: Now Expects Net Sales To Decline Of 2.5% To Decline Of 1.7% (Prior Decline Of 4% To Decline Of 2%); Revises Adjusted EPS Forecast To $3.15-$3.28 (Prior $3.06 - $3.26) Vs. $3.18 Est.

Comments

Tornado Global Hydrovacs

News

Latest news for Tornado Global Hydrovacs (OTC:TGHLF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga